CSIMarket
 


Hcw Biologics Inc   (HCWB)
Other Ticker:  
 

Hcw Biologics Inc 's Working Capital Ratio

HCWB's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 2.56 below Hcw Biologics Inc average.

Within Major Pharmaceutical Preparations industry 341 other companies have achieved higher Working Capital Ratio than Hcw Biologics Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1061 to 1754.

Explain Working Capital Ratio
How much in Current Assets HCWB´s has?
What is the value of HCWB´s Current Liabilities?


HCWB Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 136.22 % 296.5 % 219.03 % 27.35 % -4.23 %
Y / Y Current Assets Change -51.76 % -42.82 % -21.01 % -15.83 % -34.09 %
Working Capital Ratio MRQ 2.56 4.36 6.62 11.52 12.52
HCWB's Total Ranking # 1754 # 1061 # 573 # 330 # 304
Seq. Current Liabilities Change 19.37 % 0.35 % 52.95 % 28.93 % 100.36 %
Seq. Current Assets Change -30.06 % -33.87 % -12.12 % 18.68 % -17.1 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 342
Healthcare Sector # 664
Overall Market # 1754


Working Capital Ratio Statistics
High Average Low
30.26 13.26 2.41
(Jun 30 2022)   (Jun 30 2021)




Financial Statements
Hcw Biologics Inc 's Current Liabilities $ 5 Millions Visit HCWB's Balance sheet
Hcw Biologics Inc 's Current Assets $ 14 Millions Visit HCWB's Balance sheet
Source of HCWB's Sales Visit HCWB's Sales by Geography


Cumulative Hcw Biologics Inc 's Working Capital Ratio

HCWB's Working Capital Ratio for the trailling 12 Months

HCWB Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 136.22 % 296.5 % 219.03 % 27.35 % -4.23 %
Y / Y Current Assets TTM Growth -51.76 % -42.82 % -21.01 % -15.83 % -34.09 %
Working Capital Ratio TTM 5.6 7.86 11.67 17.32 19.75
Total Ranking TTM # 598 # 427 # 279 # 169 # 159
Seq. Current Liabilities TTM Growth 19.37 % 0.35 % 52.95 % 28.93 % 100.36 %
Seq. Current Assets TTM Growth -30.06 % -33.87 % -12.12 % 18.68 % -17.1 %


On the trailing twelve months basis Due to increase in Current Liabilities in the III Quarter 2023 to $5.42 millions, cumulative Working Capital Ratio decreased to 5.6 below the Hcw Biologics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 491 other companies have achieved higher Working Capital Ratio than Hcw Biologics Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3590 to 3741.

Explain Working Capital Ratio
How much in Current Assets HCWB´s has?
What is the value of HCWB´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 492
Healthcare Sector # 1021
Within the Market # 1754


trailing twelve months Working Capital Ratio Statistics
High Average Low
21.51 13.57 5.6
(Jun 30 2022)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Marker Therapeutics inc   7.01 $ 19.487  Millions$ 2.780  Millions
Assembly Biosciences Inc   6.96 $ 49.672  Millions$ 7.132  Millions
Organigram Holdings Inc   6.95 $ 119.478  Millions$ 17.182  Millions
Lexicon Pharmaceuticals Inc   6.92 $ 223.372  Millions$ 32.261  Millions
Aldeyra Therapeutics Inc   6.83 $ 147.210  Millions$ 21.552  Millions
Liquidia Corporation  6.83 $ 82.980  Millions$ 12.156  Millions
China Health Industries Holdings Inc   6.82 $ 40.656  Millions$ 5.961  Millions
Intra cellular Therapies Inc   6.81 $ 702.425  Millions$ 103.092  Millions
Abeona Therapeutics Inc   6.81 $ 57.264  Millions$ 8.412  Millions
Marinus Pharmaceuticals Inc   6.81 $ 195.040  Millions$ 28.654  Millions
Enanta Pharmaceuticals Inc  6.73 $ 422.791  Millions$ 62.787  Millions
Arcutis Biotherapeutics Inc   6.72 $ 281.548  Millions$ 41.889  Millions
Bolt Biotherapeutics Inc   6.69 $ 125.466  Millions$ 18.751  Millions
Coya Therapeutics Inc   6.54 $ 11.823  Millions$ 1.807  Millions
Rhythm Pharmaceuticals inc   6.51 $ 329.201  Millions$ 50.586  Millions
Inflarx N v   6.50 $ 122.605  Millions$ 18.866  Millions
Aadi Bioscience Inc   6.48 $ 132.884  Millions$ 20.517  Millions
Trevena inc   6.41 $ 39.478  Millions$ 6.156  Millions
Ionis Pharmaceuticals Inc  6.39 $ 2,584.650  Millions$ 404.210  Millions
Theravance Biopharma inc   6.37 $ 161.690  Millions$ 25.368  Millions
Pepgen Inc   6.35 $ 133.090  Millions$ 20.955  Millions
Arbutus Biopharma Corp  6.34 $ 141.607  Millions$ 22.324  Millions
Zevra Therapeutics Inc   6.31 $ 137.013  Millions$ 21.714  Millions
Forte Biosciences Inc   6.30 $ 47.102  Millions$ 7.471  Millions
Qilian International Holding Group Limited  6.30 $ 34.513  Millions$ 5.481  Millions
Merus N v   6.29 $ 404.832  Millions$ 64.318  Millions
Pds Biotechnology Corp  6.21 $ 56.838  Millions$ 9.154  Millions
Praxis Precision Medicines Inc   6.15 $ 103.327  Millions$ 16.792  Millions
Citius Pharmaceuticals Inc   5.95 $ 34.408  Millions$ 5.779  Millions
Regeneron Pharmaceuticals Inc   5.86 $ 18,634.800  Millions$ 3,181.300  Millions

Date modified: 2023-11-16T19:14:12+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com